3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
14
Leukemia, Myeloid, Acute
7
Neoplasms
3
Neoplasm Metastasis
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neuroblastoma
2
Liver Neoplasms
2
Hepatoblastoma
2
Fibrolamellar hepatocellular carcinoma
2
Tongue Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Sarcoma, Myeloid
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
1
Melanoma
1
Gastrointestinal Stromal Tumors
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
70
Nivolumab
69
cabozantinib
44
Ipilimumab
39
Specimen Handling
33
Magnetic Resonance Spectroscopy
33
lenvatinib
26
Axitinib
25
belzutifan
21
Sunitinib
18
Biopsy
15
Radiosurgery
14
CTLA-4 Antigen
14
atezolizumab
11
Everolimus
10
pazopanib
8
fludarabine
8
avelumab
8
Cyclophosphamide
8
Bevacizumab
8
toripalimab
7
cemiplimab
7
Nephrectomy
7
Immunoglobulin G
7
aldesleukin
6
Standard of Care
6
Radiotherapy
6
Blood Specimen Collection
6
spartalizumab
5
palbociclib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Sorafenib
×
1 year
×
Clear all
NCT02184416
2026-02-27
ADONIS
Pfizer
Completed
554 enrolled